StockSignal
  • Screen for fundamentally interesting stocks
Sign in
Beijing Chunlizhengda Medical Instruments Co., Ltd. logo

Beijing Chunlizhengda Medical Instruments Co., Ltd.

1858 · XHKG · Medical Devices · China

Gross Profit MarginProfitable 3y
Market Capitalization10.00B HKD
Trailing P/E26.92 HKD
52-Week Change27.15 HKD
Forward Annual Dividend Yield7.15%
Beta-0.0840 HKD

Beijing Chunlizhengda Medical Instruments Co., Ltd. is a prominent enterprise within the medical technology sector, specializing in the research, development, and manufacturing of medical devices and orthopedic implants. The company's primary focus lies in providing innovative and high-quality medical instruments that support healthcare professionals in improving patient outcomes. Notably, Chunlizhengda produces a range of orthopedic products including artificial joints, spine products, trauma products, and surgical instruments. These products play a critical role in sectors such as surgical orthopedics and rehabilitation, contributing significantly to patient mobility and recovery. Established in Beijing, this company showcases a commitment to technological advancement and excellence in medical device manufacturing. Its influence extends beyond China, as it seeks to expand its footprint in global markets, offering durable and reliable solutions for healthcare systems worldwide.

Industry

Medical Devices

Healthcare sector · China

Stories

Structural patterns identified in Beijing Chunlizhengda Medical Instruments Co., Ltd.

No stories identified yet.

Key Metrics

Market Capitalization
10.00BHKD
NormalMar 18, 2026
Trailing P/E
26.92HKD
NormalMar 18, 2026
Revenue (TTM)
1.18BHKD
NormalMar 18, 2026
Profit Margin
26.07%
NormalMar 18, 2026
Beta
-0.0840HKD
NormalMar 18, 2026
52-Week Change
27.15HKD
ExtremeMar 18, 2026
Forward Annual Dividend Yield
7.15%
NormalMar 18, 2026
Forward Yield
7.15%
Above 5Y avg (0.94%)
Annual Rate
HKD 0.92
Paid annual
Payout Ratio
31.6%
Sustainable
Loading dividend history...

Track Record

Frequency
Annual

Upcoming

Ex-Dividend Date
Nov 24, 2025

Screen for dividend patterns

Find other stocks with similar dividend characteristics in the screener.

Dividend Fortress
→
dividend consistency
dividend quality
free cash flow conversion
Open in Screener
Dividend Growth Track
→
dividend growth rate
dividend streak
dividend consistency
Open in Screener
Dividend Sustainability
→
dividend quality
common dividends to free cash flow
dividend stress
Open in Screener
Valuation9
Market Capitalization
10.00BHKD
NormalMar 18, 2026
Enterprise Value
3.22BHKD
NormalMar 18, 2026
Trailing P/E
26.92HKD
NormalMar 18, 2026
Forward P/E
14.36HKD
NormalMar 18, 2026
PEG Ratio
14.36HKD
ExtremeMar 18, 2026
Price to Sales (TTM)
7.37HKD
NormalMar 18, 2026
Price to Book (MRQ)
1.46HKD
NormalMar 18, 2026
Enterprise to Revenue
2.72HKD
NormalMar 18, 2026
Enterprise to EBITDA
8.40HKD
NormalMar 18, 2026
Profitability & Growth56
Profit Margin
26.07%
NormalMar 18, 2026
Operating Margin
27.11%
NormalMar 18, 2026
Return on Assets (TTM)
0.0361HKD
NormalMar 18, 2026
Return on Equity (TTM)
0.0937HKD
NormalMar 18, 2026
Revenue (TTM)
1.18BHKD
NormalMar 18, 2026
Revenue per Share (TTM)
2.72HKD
NormalMar 18, 2026
Quarterly Revenue Growth
-0.0330HKD
NormalMar 18, 2026
Gross Profit (TTM)
1.18BHKD
NormalMar 18, 2026
EBITDA
169.47MHKD
ExtremeMar 18, 2026
Net Income (TTM)
308.85MHKD
NormalMar 18, 2026
Quarterly Earnings Growth (YoY)
0.2620HKD
NormalMar 18, 2026
Operating Cash Flow (TTM)
51.83MHKD
NormalMar 18, 2026
Levered Free Cash Flow (TTM)
124.99MHKD
NormalMar 18, 2026
Forward Annual Dividend Rate
0.9216HKD
NormalMar 18, 2026
Forward Annual Dividend Yield
7.15%
NormalMar 18, 2026
Trailing Annual Dividend Rate
0.2304HKD
NormalMar 18, 2026
Trailing Annual Dividend Yield
1.79%
NormalMar 18, 2026
5-Year Average Dividend Yield
94.00%
ExtremeMar 18, 2026
Payout Ratio
0.3162HKD
NormalMar 18, 2026
Minority Interest (Equity)
1.44M
NormalFY2024 · Dec 31, 2024
Revenue
805.86M
NormalFY2024 · Dec 31, 2024
Cost of Goods Sold
268.95M
NormalFY2024 · Dec 31, 2024
Gross Profit
536.90M
NormalFY2024 · Dec 31, 2024
Operating Income
131.96M
NormalFY2024 · Dec 31, 2024
Pre-tax Income
131.60M
NormalFY2024 · Dec 31, 2024
Income Tax Expense
6.94M
NormalFY2024 · Dec 31, 2024
Net Income
124.66M
NormalFY2024 · Dec 31, 2024
EBIT
131.64M
NormalFY2024 · Dec 31, 2024
ebitda-income
169.47M
NormalFY2024 · Dec 31, 2024
Research & Development
133.10M
NormalFY2024 · Dec 31, 2024
Selling, General & Administrative
178.06M
NormalFY2024 · Dec 31, 2024
Other Operating Expenses
5.56M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Income
16.31M
NormalFY2024 · Dec 31, 2024
Non-operating Interest Expense
44.94K
NormalFY2024 · Dec 31, 2024
EPS (Basic)
0.3300
NormalFY2024 · Dec 31, 2024
EPS (Diluted)
0.3300
NormalFY2024 · Dec 31, 2024
Basic Shares Outstanding
378.75MShares
NormalFY2024 · Dec 31, 2024
Diluted Shares Outstanding
378.75MShares
NormalFY2024 · Dec 31, 2024
Net Income from Continuing Operations
124.66M
NormalFY2024 · Dec 31, 2024
Minority Interests (P&L)
326.73K
NormalFY2024 · Dec 31, 2024
Preferred Stock Dividends
0.00
NormalFY2024 · Dec 31, 2024
Operating Cash Flow
51.83M
NormalFY2024 · Dec 31, 2024
Free Cash Flow
-51.07M
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents (End of Period)
1.14B
NormalFY2024 · Dec 31, 2024
Net Income (CF Statement)
124.66M
NormalFY2024 · Dec 31, 2024
Other Non-cash Items
-2.16M
NormalFY2024 · Dec 31, 2024
Change in Accounts Receivable (CF)
63.20M
NormalFY2024 · Dec 31, 2024
Change in Other Assets/Liabilities
-133.87M
NormalFY2024 · Dec 31, 2024
Capital Expenditures
-49.15M
NormalFY2024 · Dec 31, 2024
Net Acquisitions
-1.65M
NormalFY2024 · Dec 31, 2024
Purchase of Investments
-2.24B
NormalFY2024 · Dec 31, 2024
Sale of Investments
2.35B
NormalFY2024 · Dec 31, 2024
Net Investing Cash Flow
55.84M
NormalFY2024 · Dec 31, 2024
Common Dividends Paid
-170.53M
NormalFY2024 · Dec 31, 2024
Other Financing Charges
-12.61M
NormalFY2024 · Dec 31, 2024
Net Financing Cash Flow
-183.14M
NormalFY2024 · Dec 31, 2024
Financial Strength30
Shares Outstanding
382.19MShares
NormalMar 18, 2026
Float Shares
156.43MHKD
NormalMar 18, 2026
% Held by Insiders
0.0421HKD
NormalMar 18, 2026
% Held by Institutions
0.2874HKD
NormalMar 18, 2026
Total Cash (MRQ)
2.26BHKD
NormalMar 18, 2026
Total Cash per Share (MRQ)
5.22HKD
NormalMar 18, 2026
Total Debt (MRQ)
248.09KHKD
NormalMar 18, 2026
Total Debt to Equity (MRQ)
0.0070HKD
NormalMar 18, 2026
Current Ratio (MRQ)
5.89HKD
AboveNormalMar 18, 2026
Book Value per Share (MRQ)
8.87HKD
NormalMar 18, 2026
Total Assets
3.47B
NormalFY2024 · Dec 31, 2024
Total Current Assets
2.84B
NormalFY2024 · Dec 31, 2024
Total Liabilities
644.39M
NormalFY2024 · Dec 31, 2024
Total Non-current Assets
625.25M
NormalFY2024 · Dec 31, 2024
Total Non-current Liabilities
97.65M
NormalFY2024 · Dec 31, 2024
Total Current Liabilities
546.75M
NormalFY2024 · Dec 31, 2024
Cash
1.14B
NormalFY2024 · Dec 31, 2024
Cash Equivalents
355.59K
NormalFY2024 · Dec 31, 2024
Cash & Cash Equivalents
1.14B
NormalFY2024 · Dec 31, 2024
Other Short-term Investments
745.80M
NormalFY2024 · Dec 31, 2024
Accounts Receivable
218.66M
NormalFY2024 · Dec 31, 2024
Inventory
550.84M
NormalFY2024 · Dec 31, 2024
Accounts Payable
227.85M
NormalFY2024 · Dec 31, 2024
Short-term Debt
682.12K
NormalFY2024 · Dec 31, 2024
Other Current Liabilities
52.60K
NormalFY2024 · Dec 31, 2024
Long-term Debt
184.31K
NormalFY2024 · Dec 31, 2024
Common Stock (Book)
383.57M
NormalFY2024 · Dec 31, 2024
Retained Earnings
1.21B
NormalFY2024 · Dec 31, 2024
Total Shareholders' Equity
2.82B
NormalFY2024 · Dec 31, 2024
Treasury Stock
12.02M
ExtremeFY2024 · Dec 31, 2024
Market & Technical9
52-Week Low
8.35HKD
NormalMar 18, 2026
52-Week High
20.82HKD
NormalMar 18, 2026
52-Week Change
27.15HKD
ExtremeMar 18, 2026
Beta
-0.0840HKD
NormalMar 18, 2026
50-Day MA
14.17HKD
NormalMar 18, 2026
200-Day MA
15.14HKD
NormalMar 18, 2026
Avg 10-Day Volume
471.89KHKD
NormalMar 18, 2026
Avg 30-Day Volume
624.77KHKD
NormalMar 18, 2026
Diluted EPS (TTM)
0.4800HKD
NormalMar 18, 2026

Coordination

Placeholder CorpCoordination
Example HoldingsCoordination
Sample IncCoordination

Supply Chain

Medical Devices Supply Chain

The medical devices supply chain is shaped by three structural constraints that most manufacturing industries do not face: a regulatory classification cascade where risk level determines the years of validation required before a product can be sold, sterilization and biocompatibility requirements that restrict which materials and processes are permitted, and installed base dependency where hospitals commit to ecosystems that cannot be switched without replacing training, consumables, and data infrastructure.

StockSignal
  • Blog
  • Industries
  • Glossary
  • Stories
  • Coordinations
  • Constraint Archetypes
  • Legal

Contact

© 2026 StockSignal. All rights reserved.